Healthcare, biotechnology & medical AI Product
EchoGo Core measures cardiac function and EchoGo Amyloidosis has a separate screening role
Ultromics’ EchoGo Core quantifies cardiac function from ultrasound images. EchoGo Amyloidosis 1.0 is a separately cleared echocardiography-based screening aid for the specific adult population in its labeling. [1][2]
What it does
The FDA cleared EchoGo Core on November 13, 2019, under K191171 and EchoGo Amyloidosis 1.0 on November 15, 2024, under K240860. [1][2]
Why it matters
The regulatory records distinguish general quantification and reporting from condition-specific decision support in the same product family. [1][2]
Who it’s for
The named products support professionals interpreting echocardiograms. The Amyloidosis 1.0 indication addresses adults over 65 with heart failure in the specified assessment setting. [1][2]
Key dates
Where it fits
EchoGo Core returns measures of cardiac function. EchoGo Amyloidosis 1.0 produces separate screening information for professional interpretation. [1][2]
Limits and trade-offs
The adult population specified in the Amyloidosis 1.0 filing belongs to that device’s indication. Both products have supporting clinical roles. [1][2]
Sources and verification
Catalog evidence checked How we verify records
- Primary source FDA 510(k) decision for EchoGo Amyloidosis (1.0) (K240860)
- Primary source FDA 510(k) decision for EchoGo Core (K191171)
Related profiles
Healthcare, biotechnology & medical AI
Sleep Analysis Module (SAM)
Neurotronics (Nihon Kohden)
The module estimates sleep time from a signal captured during its intended sleep-testing workflow.
Healthcare, biotechnology & medical AI
Heartvue.Proton
Heartvue.ai
It is software for analyzing cardiac MRI images within its documented intended-use scope.
Healthcare, biotechnology & medical AI
ThinkSono Guidance
ThinkSono
Provides guidance during acquisition of lower-extremity compression ultrasound images for review by healthcare professionals.